Over the next three months, the U.S. Food and Drug Administration (FDA) will be issuing several pivotal decisions that could significantly impact the biopharma market. In particular, FDA approvals are pending for five critical drugs from companies such as BridgeBio Pharma, AstraZeneca, Daiichi
The recent partnership between Somite Therapeutics and OmniaBio Inc. marks a promising leap forward in treating Duchenne muscular dystrophy (DMD). Combining Somite's AI-driven approach with OmniaBio's cell and gene therapy expertise, this collaboration aims to expedite the development of advanced
In a significant move that is set to reshape the biopharmaceutical landscape, Tanvex BioPharma is acquiring Bora Biologics, a subsidiary of Bora Pharmaceuticals. This strategic merger aims to amalgamate the strengths of two industry leaders, creating a formidable force in the global Contract
Theravance Biopharma Inc (NASDAQ: TBPH) has been navigating a complex landscape filled with mixed signals, affecting its market performance and generating varied sentiment among analysts and investors alike. This article delves into recent developments surrounding the company, including key
The recent decision by the Supreme Court to overturn the Chevron doctrine marks a significant shift in administrative law, with profound implications for the healthcare industry, particularly for federal regulators like the FDA (Food and Drug Administration) and the CMS (Centers for Medicare &
In an era where sustainability is no longer an option but a necessity, the pharmaceutical industry finds itself grappling with significant challenges in its commitment to sustainable practices. A recent survey by Cytiva and FT Longitude paints a complex picture of the industry’s sustainability
Quantum BioPharma Ltd. (NASDAQ: QNTM, CSE: QNTM), formerly FSD Pharma Inc., has embarked on a transformative journey within the biopharmaceutical sector. As of August 15, 2024, the company has undertaken significant steps to revitalize its brand and align its strategic focus on innovative solutions
Vanguard Group Inc. has significantly bolstered its investment in Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company known for its development of antibody drug conjugates (ADCs). According to the most recent 13F filing with the Securities and Exchange Commission (SEC), Vanguard
In the rapidly evolving field of biopharmaceuticals, the quest for high-quality biologics hinges on the ability to thoroughly analyze and understand complex protein structures. The critical role of proteomics—a branch of biochemistry focused on the study of proteins—cannot be overstated. As demand
The pharmaceutical industry is undergoing a significant transformation driven by the integration of data analytics, reshaping various aspects such as drug discovery, clinical trials, supply chain management, and commercial strategies. This change is not just a trend but a necessity as the industry
ITCurated uses cookies to personalize your experience on our website. By continuing to use this site, you agree to our Cookie Policy